Resveratrol is a polyphenol found in red wine, grapes, berries, and peanuts. In 2003, David Sinclair's lab at Harvard published a landmark paper showing resveratrol activated Sir2 (a sirtuin deacetylase) and extended lifespan in yeast by 70%. A supplement industry was born.
Two decades and hundreds of human trials later, the clinical evidence ranges from modest to null. Resveratrol is one of the clearest examples in supplement science of how animal research fails to predict human outcomes.
What resveratrol is and what it does (in cells)
Resveratrol (3,5,4′-trihydroxystilbene) is produced by plants under stress — UV radiation, fungal infection, injury. It's a defense compound.
Mechanisms identified in cell culture and animal research:
- SIRT1 activation (sirtuin deacetylase involved in metabolic regulation and longevity)
- AMPK activation (energy sensing pathway)
- NF-κB inhibition (anti-inflammatory)
- mTOR inhibition (longevity-associated pathway)
- Antioxidant activity
- Mitochondrial biogenesis via PGC-1α
The mechanism portfolio looks excellent on paper. Every one of these pathways is associated with health and longevity research.
The animal research that launched the industry
Howitz et al. (2003, Nature): Resveratrol extended lifespan in yeast by 70% via Sir2 activation. Sinclair's lab. This paper made global news.
Baur et al. (2006, Nature): High-dose resveratrol (22mg/kg/day) improved health span and survival in obese mice fed a high-fat diet. Reduced cardiovascular disease markers. More headlines.
Subsequent animal work: Life extension in worms, flies, fish. Metabolic improvements in obese rodents. Cognitive benefits in aged mice.
The animal data is real and impressive. This is not a fabricated story — it's a story about species-specific biology.
Why human translation failed
Bioavailability
Resveratrol is rapidly metabolized in the gut and liver. After oral ingestion, it's converted to sulfate and glucuronide conjugates within minutes. Free resveratrol plasma concentrations are extremely low regardless of dose.
Pharmacodynamic studies show peak free resveratrol plasma levels of nanomoles per liter after gram doses — far below concentrations used in cell culture studies (typically micromolar). The concentration that activates SIRT1 in vitro may never be achieved in human tissues with oral supplementation.
SIRT1 activation debate
Bauer et al. (2010) and other labs demonstrated that Sinclair's original SIRT1 activation assay used a fluorescent label that artificially enhanced the activation signal. Without the fluorescent substrate, resveratrol's SIRT1 activation was dramatically weaker.
This sparked a scientific controversy that was partly resolved — resveratrol does activate SIRT1 in some contexts — but the original potency was overstated. The compound that became a billion-dollar industry was partly built on an assay artifact.
Human caloric restriction equivalence
The animal longevity effects required very high doses and were most dramatic in obese mice. The proposed mechanism was mimicking caloric restriction. But healthy humans eating normal diets don't show the same metabolic starting point.
What the human clinical trials show
Cardiovascular outcomes
Bo et al. (2013): 500mg/day resveratrol for 6 months — no significant effect on blood pressure, lipids, or inflammatory markers in healthy adults.
Pektas et al. and others: Mixed signals on endothelial function. Some studies show modest reduction in inflammatory markers; others null.
Larger meta-analyses: inconsistent effects across studies, no consistent clinically meaningful cardiovascular benefit in low-risk populations.
Type 2 diabetes / insulin sensitivity
This is the most consistently positive human domain, though effects are modest:
Timmers et al. (2011, Cell Metabolism): 150mg/day resveratrol for 30 days improved insulin sensitivity, reduced liver fat, and improved mitochondrial function in obese men. One of the few impressive human studies.
Subsequent replications: inconsistent. Some show insulin sensitivity benefit; many null results in better-controlled trials.
Exercise performance
Here, resveratrol produced a surprising negative finding:
Gliemann et al. (2013, Journal of Physiology): 250mg/day resveratrol BLUNTED cardiovascular adaptations to exercise training in older men. VO2 max and other markers improved less in the resveratrol group than placebo.
Mechanism: resveratrol's antioxidant activity may suppress the reactive oxygen species (ROS) that are required signaling molecules for aerobic adaptations. This is the same issue as antioxidant supplements blunting training adaptations.
Practical implication: Athletes should probably avoid resveratrol supplementation, particularly during training phases.
Cancer prevention
Robust in vitro and animal data. Human intervention trials have not shown cancer incidence reduction. Several clinical trials in cancer patients showed resveratrol is safe but not effective as a therapeutic.
Cognitive function / neurodegeneration
Small positive studies in older adults exist. Turner et al. (2015): 75mg twice daily improved memory performance in older adults over 26 weeks. One study; needs replication.
The CALERIE comparison
In 2022, the landmark CALERIE trial showed 25% caloric restriction in humans for 2 years produced significant improvements in aging biomarkers, insulin sensitivity, and inflammatory markers. Resveratrol as a caloric restriction mimetic does not match these effects in human trials.
The Dipasquale scandal
In 2012, researcher Dipak Das — who had published over 100 resveratrol studies at University of Connecticut — was found guilty of 145 counts of fabrication and falsification of data in resveratrol research. Many of the "confirmatory" studies of resveratrol's cardiovascular benefits were fabricated.
The scandal removed a large fraction of the published evidence base. What remained was more equivocal.
Pterostilbene: the resveratrol successor
Pterostilbene is a resveratrol analog found in blueberries with better bioavailability (~80% vs. <1%). Some researchers suggest it may achieve what resveratrol could not. Human evidence is even more limited than resveratrol — too early to draw conclusions.
Dosing (if still interested)
Studies have used 150mg–3g/day. The modest positive human studies (Timmers et al.) used 150mg. The exercise-blunting study used 250mg. Higher doses show no additional benefit and may increase drug interaction risk.
- 50–150mg/day if using at all — the low end of studied doses
- Food sources: red wine contains ~1mg/glass — irrelevant as a supplement dose
- Don't take around training — antioxidant interference with adaptations
Drug interactions
Resveratrol inhibits CYP3A4 and CYP2C9, affecting metabolism of statins, blood thinners, some calcium channel blockers, and many other drugs. High doses increase bleeding risk.
The framework applied
For any resveratrol study:
- Check the author list — post-2012, verify the researchers are not associated with Das's lab
- What dose and form? Free resveratrol vs. formulations designed for bioavailability
- Was plasma resveratrol measured? Confirms delivery to target tissues
- Healthy adults or metabolically compromised? Most positive signals come from metabolic syndrome/obese populations
- Was exercise controlled? Resveratrol + exercise may produce worse outcomes than exercise alone
We automated this at Q-SCI. Any study — paste it, get a quality score.
Bottom line
- Animal evidence is genuinely impressive; human translation has largely failed due to poor bioavailability and species-specific biology
- Most positive human signals: insulin sensitivity in obese/metabolic syndrome populations at 150mg/day
- Blunts exercise adaptations — athletes should avoid it, especially during training
- Large research fraud scandal (Das) removed a significant portion of the positive evidence base
- Not justified for healthy people seeking longevity or anti-aging benefits on current evidence
- If using: 50–150mg/day, not around training sessions, check drug interactions
Resveratrol is the cautionary tale of how compelling mechanism plus impressive animal data plus a landmark paper can create a billion-dollar supplement category that clinical evidence doesn't support.
More evidence-based analyses at q-sci.org/blog. Score studies free at q-sci.org.
Top comments (0)